Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human tetranectin: methodological and clinical studies

C K Høgdall1

  • 1Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, Denmark.

APMIS. Supplementum
|December 30, 1998
PubMed
Summary

Tetranectin (TN) aids in proteolysis and can be a cancer marker. Monoclonal antibodies (MAbs) against TN were developed for diagnostic and prognostic studies in ovarian and breast cancers, showing TN

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An overview of Clinical Quality Registries (CQRs) on gynecological oncology worldwide.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2022
Same author

The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.

Gynecologic oncology·2019
Same author

Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

British journal of cancer·2009
Same author

Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables.

European journal of gynaecological oncology·2006
Same author

Tetranectin in cerebrospinal fluid of patients with multiple sclerosis.

Scandinavian journal of clinical and laboratory investigation·2006
Same author

Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.

Endocrine-related cancer·2005

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Tetranectin (TN) is implicated in proteolysis by binding plasminogen, enhancing its activation to plasmin.
  • Increased extracellular proteolysis is linked to cancer cell infiltration and metastasis, suggesting TN's potential as a biomarker.
  • Previous studies have explored TN's role in various clinical conditions involving heightened proteolysis.

Purpose of the Study:

  • To develop and characterize monoclonal antibodies (MAbs) against human tetranectin (TN).
  • To investigate the clinical significance of TN levels in blood and tissues for cancer diagnosis and prognosis.
  • To evaluate TN's utility as a biomarker in ovarian and breast cancer.

Main Methods:

  • Production and characterization of five monoclonal antibodies (MAbs) against human TN.
  • Epitope mapping using enzyme immunoassay and isotachophoresis.
  • Immunohistochemical detection of TN in fresh frozen and paraffin-embedded tissues.
  • Analysis of serum/plasma TN (s/p-TN) and tissue TN levels in ovarian and breast cancer patients.
  • Correlation of TN levels with diagnostic markers (CA 125, CASA), tumor characteristics, treatment response, and patient survival.

Main Results:

  • Five stable hybridomas producing MAbs against human TN were established, defining two epitope groups.
  • MAbs were suitable for enzyme immunoassays and immunohistochemistry, facilitating TN studies.
  • In ovarian cancer, s/p-TN combined with CA 125 improved diagnostic sensitivity and specificity.
  • Preoperative s-TN correlated with residual tumor and survival in ovarian cancer patients.
  • Low p-TN and heavy stromal TN staining indicated poor prognosis in ovarian cancer patients.
  • Serum TN (s-TN) was a strong independent prognostic factor for poor treatment response and survival in metastatic breast cancer patients.
  • A decrease in TN concentration during chemotherapy predicted recurrence in ovarian cancer patients.

Conclusions:

  • Developed MAbs are valuable tools for future research on TN's structure, function, and clinical relevance.
  • TN, particularly in conjunction with CA 125, shows promise as a screening and prognostic marker for ovarian cancer.
  • TN levels and tissue staining provide significant prognostic information for ovarian cancer patients, aiding treatment decisions.
  • Serum TN is a critical prognostic indicator in metastatic breast cancer, suggesting potential for treatment monitoring and modification.

Related Experiment Videos